Patient and Oncologist Preferences for ALK plus Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitor Treatments

被引：0
|
作者：
Le, H. [1 ]
Coulter, J. [2 ]
Cappelleri, J. C. [2 ]
Lu, H. [3 ]
Quaife, M. [3 ]
Meginnis, K. [3 ]
Fernandez, G. [3 ]
Culver, K. [4 ]
Vaghela, S. [2 ]
Rifi, N. [2 ]
Stinchcombe, T. [5 ]
机构：
[1] Pfizer Inc, Fairfax, VA USA
[2] Pfizer Inc, New York, NY USA
[3] Evidera, Cambridge, England
[4] ALK Posit, Atlanta, GA USA
[5] Duke Hlth, Durham, NC USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Preference; ALK; TKI;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.12B.05
引用
收藏
页码：S202 / S202
页数：1
相关论文
共 50 条
  • [41] Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK plus ) advanced non-small cell lung cancer (NSCLC).
    Felip, Enriqueta
    De Braud, Filippo G.
    Maur, Michela
    Loong, Herbert H. F.
    Shaw, Alice Tsang
    Vansteenkiste, Johan F.
    John, Tom
    Liu, Geoffrey
    Lolkema, Martijn P.
    Scott, Jeffrey W.
    Yu, Richard
    Selvaggi, Giovanni
    Mishra, Kaushal
    Lau, Yi-Yang Yvonne
    Tan, Daniel Shao-Weng
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Tyrosine kinase inhibitors in the management of non-small cell lung cancer
    Perol, M.
    Arpin, D.
    REVUE DES MALADIES RESPIRATOIRES, 2007, 24 (08) : S188 - S197
  • [43] The Radiosensitivity of Tyrosine Kinase Driven Non-small Cell Lung Cancer
    Johung, K. L.
    Yu, J. B.
    Gettinger, S. N.
    Decker, R. H.
    Hess, J. A.
    Chiang, V. L.
    Contessa, J. N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S115 - S115
  • [44] Treatment sequencing and duration of subsequent tyrosine kinase inhibitors in ALK plus non-small cell lung cancer patients treated with brigatinib in the US
    Jahanzeb, M. O.
    Lin, H. M.
    Wu, Y.
    Gorritz, M.
    McGuiness, C. B.
    Sun, K.
    Chen, C-C.
    Zhang, P.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S960 - S961
  • [45] Receptor tyrosine kinase mutations in non-small cell lung cancer
    Hayashi, H.
    Togashi, Y.
    Terashima, M.
    Sakai, K.
    Mizuuchi, H.
    Kobayashi, Y.
    Suda, K.
    Nakagawa, K.
    Nishio, K.
    Mitsudomi, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S601 - S601
  • [46] Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial
    Kim, Dong-Wan
    Mehra, Ranee
    Tan, Daniel Shao-Weng
    Felip, Enriqueta
    Chow, Laura Quan Man
    Camidge, D. Ross
    Vansteenkiste, Johan F.
    Sharma, Sunil
    De Pas, Tommaso
    Riely, Gregory J.
    Solomon, Benjamin J.
    Wolf, Juergen
    Thomas, Michael
    Schuler, Martin H.
    Liu, Geoffrey
    Santoro, Armando
    Geraldes, Margarida
    Boral, Anthony
    Yovine, Alejandro Javier
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Therapeutic strategies in advanced ALK positive non-small cell lung cancer
    Tiotiu, A.
    Billon, Y.
    Vaillant, P.
    Menard, O.
    Hofman, P.
    Mascaux, C.
    REVUE DES MALADIES RESPIRATOIRES, 2019, 36 (10) : 1107 - 1116
  • [48] Chemotherapy or tyrosine kinase inhibitor for second line treatment in advanced non small cell lung cancer
    Jyoti, B.
    McKay, M.
    Wong, H.
    Alam, F.
    Eswar, C.
    Jain, P.
    Littler, J. A. H.
    Maguire, J.
    Schofield, C. P.
    Siva, A.
    Ramani, V. S.
    LUNG CANCER, 2012, 75 : S6 - S6
  • [49] Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report
    Hu, Han
    Dai, Hui
    Ding, Liren
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (08) : 2967 - 2972
  • [50] ACTIVATION OF CYTOMEGALOVIRUS IN A PATIENT ON EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR TREATMENT IN NON-SMALL CELL LUNG CANCER
    Dawes, Sean M.
    Plichta, Christine
    Gaddipati, Himaja
    Hamade, Sam
    Biedny, Adam
    de Villate, Oscar F. Parodi Ortiz
    CHEST, 2023, 164 (04) : 972A - 973A
12345